3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Myeloid Malignancies
1
Multiple Myeloma
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Colorectal Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
apatinib
3
vistusertib
2
olaparib
2
camrelizumab
2
atezolizumab
2
Ipilimumab
2
Everolimus
2
trametinib
1
toripalimab
1
tilsotolimod
1
tazemetostat
1
tazarotene
1
spartalizumab
1
seviteronel
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
roniciclib
1
romiplostim
1
pyrotinib
1
phosphorylethanolamine
1
pemigatinib
1
pembrolizumab
1
pazopanib
1
palbociclib
1
niraparib
1
magrolimab
1
lenvatinib
1
irinotecan sucrosofate
1
famitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Solid Tumor
×
magrolimab
×
Clear all
NCT04827576
2025-05-08
ELEVATELung&UC
Gilead Sciences
Phase 2
Terminated
106 enrolled
22 charts